Purinergic receptors P2RX4 and P2RX7 in familial multiple sclerosis.
Genetic variants in the purinergic receptors P2RX4 and P2RX7 have been shown to affect susceptibility to multiple sclerosis (MS). In this study, we set out to evaluate whether rare coding variants of major effect could also be identified in these purinergic receptors. Sequencing analysis of P2RX4 and P2RX7 in 193 MS patients and 100 controls led to the identification of a rare three variant haplotype (P2RX7 rs140915863:C>T [p.T205M], P2RX7 rs201921967:A>G [p.N361S], and P2RX4 rs765866317:G>A [p.G135S]) segregating with disease in a multi-incident family with six family members diagnosed with MS (logarithm of odds = 3.07). Functional analysis of this haplotype in HEK293 cells revealed impaired P2X7 surface expression (P < 0.01), resulting in over 95% inhibition of adenosine triphosphate (ATP)-induced pore function (P < 0.001) and a marked reduction in phagocytic ability (P < 0.05). In addition, transfected cells showed 40% increased peak ATP-induced inward current (P < 0.01), and a greater Ca2+response to the P2X4 135S variant compared with wild type (P < 0.0001). Our study nominates rare genetic variants in P2RX4 and P2RX7 as major genetic contributors to disease, further supporting a role for these purinergic receptors in MS and the disruption of transmembrane cation channels leading to impairment of phagocytosis as the pathological mechanisms of disease.
Department of Medical Genetics, University of British Columbia, Vancouver, Canada.|Division of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
A Dessa
AD
Sadovnick
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
Ben J
BJ
Gu
Division of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
Anthony L
AL
Traboulsee
Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
Cecily Q
CQ
Bernales
Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
Mary
M
Encarnacion
Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
Irene M
IM
Yee
Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
Maria G
MG
Criscuoli
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
Xin
X
Huang
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
Amber
A
Ou
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
Carol J
CJ
Milligan
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
Steven
S
Petrou
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
James S
JS
Wiley
Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
Carles
C
Vilariño-Güell
D005260:Female; D020022:Genetic Predisposition to Disease; D057809:HEK293 Cells; D006239:Haplotypes; D006801:Humans; D008297:Male; D009103:Multiple Sclerosis / Q000235:genetics* / Q000473:pathology; D020641:Polymorphism, Single Nucleotide; D058848:Receptors, Purinergic P2X4 / Q000235:genetics*; D058486:Receptors, Purinergic P2X7 / Q000235:genetics*
C548226:P2RX4 protein, human; C546468:P2RX7 protein, human; D058848:Receptors, Purinergic P2X4; D058486:Receptors, Purinergic P2X7
P2RX4, P2RX7, P2X4, P2X7, variant; familial, Mendelian, multiple sclerosis; mutation